Please wait while we load the requested 10-Q report or click the link below:
FOR IMMEDIATE RELEASE
TherapeuticsMD Announces Second Quarter 2017 Financial Results
Second Quarter and Recent Developments
|||Net revenue for the company’s prescription prenatal vitamin business was approximately $4.3 million for the second quarter of 2017 compared with approximately $4.4 million for the second quarter of 2016.|
|||Net loss was approximately $19.7 million for the second quarter of 2017, compared with approximately $21.1 million for the second quarter of 2016.|
|||Ended the quarter with approximately $96.5 million in cash and no debt.|
|||Participated in a Type A Post-Action Meeting on June 14, 2017 with the Division of Bone, Reproductive, and Urologic Products (DBRUP) of the FDA to discuss the Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The Company has formally submitted additional information for consideration related to the NDA for TX-004HR and has been informed by the FDA that it will be receiving an Advice Letter within the next week outlining the FDA’s timing of its review of the submitted additional data.|
|||Pre-NDA meeting for TX-001HR, the company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause, scheduled with the FDA at the end of August 2017. The company anticipates that it will submit the NDA for TX-001HR in the fourth quarter of 2017.|
|||Dismissal without prejudice of the primary federal securities class action lawsuit recently filed against the company.|
|||Grew the company’s intellectual property portfolio to a current total of 158 patent filings, including 82 international filings, with one allowed and 17 issued U.S. patents.|
“We continue to focus on advancing our pipeline of novel hormone therapies and, if approved, bringing new, differentiated treatment options to women suffering from symptoms of menopause,” said TherapeuticsMD CEO Robert G. Finizio.
Summary of Second Quarter 2017 Financial Results
Net revenue from the company’s prescription prenatal vitamin business was approximately $4.3 million for the second quarter of 2017 compared with net revenue of approximately $4.4 million for the prior year’s quarter. These changes were primarily due to a decrease in the number of units sold.
Cost of goods sold was approximately $0.7 million for the second quarter of 2017, compared with approximately $1.1 million for the prior year’s quarter.
Total operating expenses for the second quarter of 2017 included research and development (R&D) expenses and sales, general, and administrative expenses (SG&A). R&D expenses for the second quarter of 2017 were approximately $8.7 million compared with approximately $13.8 million for the prior year’s quarter. The decrease in R&D expenses was a direct result of the completion of the REPLENISH Trial for TX-001HR. SG&A expenses for the second quarter of 2017 were approximately $14.6 million compared with approximately $10.6 million for the prior year’s quarter, primarily due to higher sales, marketing, regulatory expenditures, and personnel costs to support future commercialization.
Net loss for the second quarter of 2017 was approximately $19.7 million, or $0.10 per basic and diluted share, compared with approximately $21.1 million, or $0.11 per basic and diluted share, for the second quarter of 2016.
At June 30, 2017, cash on hand was approximately $96.5 million, compared with approximately $131.5 million at December 31, 2016.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s late stage clinical pipeline includes two phase 3 product candidates: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to resolve the deficiencies identified by the FDA in the company’s new drug application for its TX-004HR product candidate and the time frame associated with such resolution; whether the company will be able to prepare an amended NDA for its TX-004HR product candidate and, if prepared, whether the FDA will accept and approve the NDA; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to prepare an NDA for its TX-001HR product candidate and, if prepared, whether the FDA will accept and approve the NDA; the length, cost and uncertain results of the company’s clinical trials, including any additional clinical trials that the FDA may require in connection with TX-004HR; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
# # #
Director, Investor Relations
|June 30, 2017||December 31, 2016|
|Accounts receivable, net of allowance for doubtful accounts|
|of $358,268 and $376,374, respectively||3,396,419||4,500,699|
|Other current assets||2,228,755||2,299,052|
|Total current assets||103,515,672||139,410,173|
|Fixed assets, net||483,688||516,839|
|Intangible assets, net||2,739,686||2,405,972|
|Total other assets||2,878,722||2,545,008|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Other current liabilities||5,180,218||7,624,085|
|Total current liabilities||13,288,252||14,982,599|
|Commitments and Contingencies|
|Preferred stock - par value $0.001; 10,000,000 shares authorized;|
|no shares issued and outstanding||—||—|
|Common stock - par value $0.001; 350,000,000 shares authorized;|
|204,027,142 and 196,688,222 issued and outstanding, respectively||204,027||196,688|
|Additional paid in capital||443,952,952||436,995,052|
|Total stockholders' equity||93,589,830||127,489,421|
|Total liabilities and stockholders' equity||$||106,878,082||$||142,472,020|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Cost of goods sold||681,725||1,130,108||1,341,360||2,238,551|
|Sales, general, and administration||14,628,927||10,619,006||31,466,544||20,297,558|
|Research and development||8,716,395||13,841,193||16,441,235||28,938,210|
|Depreciation and amortization||53,189||24,262||102,888||43,859|
|Total operating expense||23,398,511||24,484,461||48,010,667||49,279,627|
|Total other income||152,886||117,183||282,721||161,336|
|Loss before taxes||(19,676,917||)||(21,094,139||)||(40,833,409||)||(42,023,504||)|
|Provision for income taxes||—||—||—||—|
|Net loss per share, basic and diluted||$||(0.10||)||$||(0.11||)||$||(0.20||)||$||(0.21||)|
|Weighted average number of common|
|Six Months Ended|
|June 30, 2017||June 30, 2016|
|CASH FLOWS FROM OPERATING ACTIVITIES|
|Adjustments to reconcile net loss to net cash flows used in|
|Depreciation of fixed assets||69,000||19,216|
|Amortization of intangible assets||33,888||24,643|
|(Recovery of) provision for doubtful accounts||(18,106||)||447,388|
|Changes in operating assets and liabilities:|
|Other current assets||(58,601||)||1,001,120|
|Other current liabilities||(2,443,867||)||(1,239,743||)|
|Net cash used in operating activities||(38,665,526||)||(34,725,305||)|
|CASH FLOWS FROM INVESTING ACTIVITIES|
|Purchase of fixed assets||(35,849||)||(265,036||)|
|Payment of security deposit||—||(4,864||)|
|Net cash used in investing activities||(403,451||)||(663,121||)|
|CASH FLOWS FROM FINANCING ACTIVITIES|
|Proceeds from sale of common stock, net of costs||—||134,863,475|
|Proceeds from exercise of warrants||3,798,999||1,373,000|
|Proceeds from exercise of options||212,360||978,042|
|Net cash provided by financing activities||4,011,359||137,214,517|
|(Decrease) increase in cash||(35,057,618||)||101,826,091|
|Cash, beginning of period||131,534,101||64,706,355|
|Cash, end of period||$||96,476,483||$||166,532,446|
The following information was filed by Therapeuticsmd, Inc. (TXMD) on Thursday, August 3, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Therapeuticsmd, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Therapeuticsmd, Inc..